What Maple Health Group does

Maple Health Group is a global strategy consulting firm founded in 2015 and headquartered in New York, specializing in Health Economics and Market Access (HEOR) advisory services for pharmaceutical, biotechnology, and medical device companies. The firm is organized around three integrated service lines: Market Access and Value Strategy (therapeutic-area landscape assessments, strategic evidence generation planning, payer research, and market access training), Economic Modelling and Evidence Synthesis (cost-effectiveness, cost-utility, budget impact and microsimulation models, systematic literature reviews, Bayesian network meta-analyses, MAICs, and HTA strategy and submissions), and Value Communications (global value dossiers, AMCP dossiers, payer value propositions, scientific publications, and conference materials). Underlying technical assets include proprietary Excel/VBA-based economic models, web-based pricing and access monitoring tools, and the co-developed STEER structured expert elicitation methodology that has been referenced by multiple HTA agencies.

The firm generates revenue through project-based, quote-based professional services engagements sold directly to enterprise pharma, biotech, and med-device clients; specific pricing is not publicly disclosed. Delivery is performed by a globally distributed team of senior consultants and PhD-level health economists operating from nearly a dozen countries and fluent in over 15 languages, including former NICE Technology Appraisal Committee members, ex-pharma HEOR leaders from Biogen, Pfizer, Daiichi-Sankyo, J&J, and EMD Serono, and alumni of CBPartners, BresMed/Lumanity, and BMO Capital Markets. The firm holds no patents, has no disclosed external institutional funding, and reports a headcount in the 11-50 range, with leadership concentrated in a small number of Partners and Principals plus a strategic advisor bench. Marketing is conducted primarily through a professional-services website, published case studies, and industry conference participation rather than paid or product-led channels.

By stated metrics, Maple has contributed to over 150 peer-reviewed manuscripts and poster presentations since 2015, served clients across the US, UK, EU5, and Japan, and reported in published case studies that clients renewed engagement for three subsequent years on prior workstreams. No revenue, customer logos, or contract values are publicly disclosed.

Name

Maple Health Group

Legal name

Maple Health Group, LLC

Website

https://maplehealthgroup.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

Maple Health Group is a global strategy consulting firm founded in 2015 and headquartered in New York that delivers Health Economics and Market Access advisory services - including economic modeling, evidence synthesis, HTA submissions, and value communications - to pharmaceutical, biotechnology, and medical device companies across the US, Europe, and Asia.

Ownership category

akta.pro rank

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Others

Revenue model

1. Strategic Health Economics Consulting: Project-based consulting engagements providing Health Economics and Market Access strategy services to pharmaceutical, biotech, and medical device companies. Engagements include evidence generation planning, economic modelling, HTA strategy development, and value communications development.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Maple Health Group is a global strategy consulting firm delivering Health Economics and Market Access (HEOR) services to pharmaceutical, biotechnology, and medical device companies. Its practice spans market access and value strategy (landscape assessments, evidence generation planning, payer research), economic modelling and evidence synthesis (cost-effectiveness/budget impact/microsimulation models, network meta-analyses), and value communications (global value dossiers, AMCP dossiers, payer value propositions, scientific publications).

Product overview

Maple Health Group is a global strategy consulting firm offering a unified portfolio of Health Economics and Market Access consulting services. The core offering consists of three integrated service lines: Market Access & Value Strategy (evidence generation planning, payer research, HTA engagement), Economic Modelling & Evidence Synthesis (cost-effectiveness models, budget impact models, microsimulation, NMAs, MAICs), and Value Communications (global value dossiers, AMCP dossiers, publications). These services are delivered through specific sub-products including analogue pricing monitoring, cost-utility modeling, network meta-analysis, and value demonstration strategy. The interconnected nature of these offerings allows clients to receive end-to-end support from evidence generation through to payer communications.

Differentiator

Problem solved

Functional benefit

Products and services

• Market Access & Value Strategy Strategic consulting service for pharmaceutical, biotech, and medical device companies that identifies opportunities to demonstrate product value and optimize global market access through therapeutic area landscape assessments, strategic evidence generation plans, payer research, and dynamic market access trainings.
• Economic Modelling & Evidence Synthesis Strategic consulting service providing value demonstration to policymakers through economic models, evidence synthesis and real-world evidence; includes Health Economics and HTA strategy development, cost-effectiveness/budget impact models, microsimulation models, systematic literature reviews, and network meta-analyses.
• Value Communications Strategic communication service for pharmaceutical, biotech, and medical device clients that develops publications and conference materials, payer value propositions and value messages, and industry-insight newsletters to demonstrate product value across stakeholder audiences.
• AMCP Dossier Development Development of AMCP dossiers to support US payer formulary decision-making, including targeted literature search, dossier drafting with annotations, and internal review support with medical and legal teams, for pharmaceutical manufacturers.
• Analogue Pricing and Access Monitoring Monthly monitoring service providing access, pricing, and HTA decisions tracking for competitor products across US and EU5 markets, delivered via XLS and web-based tools with strategic recommendations on pricing and market access for pharmaceutical and biotech clients.
• Cost-Utility and Budget Impact Modeling Development of cost-utility and budget impact models to communicate the economic value of pharmaceutical products, including technical documents supporting NICE submission (UK) and AMCP dossier (US).
• Indirect Treatment Comparison / Network Meta-Analysis Indirect treatment comparison service using network meta-analysis to assess clinical value of products, including systematic literature review, statistical analysis plan development, and Bayesian network meta-analysis for pharmaceutical and biotech clients.
• Value Demonstration Strategy Payer-focused evidence generation planning service delivering aspirational value proposition development, secondary and primary research validation with HTA members and US payers, and strategic recommendations for market access for pharmaceutical and biotech clients.

Quantifiable outcome

• 150+ peer-reviewed manuscripts and poster presentations contributed to since 2015
• +1 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

Feature5 records

Scale indicators4 records

Recent moves5 records

Expansion highlights5 records

Market position

Competitive moat4 records

Key highlights14 records

Customer concentration

• Xx.com/group_maple
• Facebookfacebook.com/MapleHealthGroup
• LinkedInlinkedin.com/company/maple-health-group-llc

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Maple Health Group